Zoetis Inc.

ZTS Healthcare Drug Manufacturers Specialty & Generic

Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.

79.20 0.78 +0.99%
Market cap
$32.4B
P/E
13.0×
Fwd P/E
12.3×
Dividend yield
2.64%
F-score
7/9
Altman Z
5.73
Beneish M
−2.45
Dividend safety
88/100

Zoetis Inc. (ZTS) Total debt

Alert me on Total debt

Zoetis Inc.'s total debt at the end of fiscal 2025 was $9.0B, up 37.6% from $6.6B in fiscal 2024. At the end of the quarter to 30 June 2026 it was $9.0B. Over the past ten years it has ranged from $4.5B (fiscal 2016) to $9.0B (fiscal 2025) — the current reading is the highest in ten years. Zoetis Inc. ranks 5th of 86 Drug Manufacturers Specialty & Generic companies by total debt.

Total debt, annual

Embed this chart

Annual newest first

Period Total debt Change
FY2025 $9.0B 37.63%
FY2024 $6.6B 0.05%
FY2023 $6.6B (16.92%)
FY2022 $7.9B 19.16%
FY2021 $6.6B (7.86%)
FY2020 $7.2B 11.66%
FY2019 $6.4B (0.08%)
FY2018 $6.5B 30.26%
FY2017 $5.0B 10.85%
FY2016 $4.5B (8.22%)

Quarterly newest first

Period Total debt Change
Jun 2026 $9.0B 0.03%
Mar 2026 $9.0B 0.03%
Dec 2025 $9.0B 27.91%
Sep 2025 $7.1B 7.42%
42 more quarters

Against its own ten years

Low $4.5B High $9.0B
Ten-year median $6.6B
Current reading's percentile 100

Total debt against peers

What Total debt is

Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.

Long Term Debt (Total) + Current Part of Debt

The full definition of Total debt →

More on ZTS